摘要
目的探讨血清降钙素原(PCT)在肝癌合并细菌性感染患者抗菌治疗中的临床价值。方法选择2019年1月至2020年6月嵊州市人民医院收治的100例肝癌患者为研究对象,依据是否并发细菌感染将患者分为感染组与对照组,每组各50例,以PCT浓度>0.5 ng/ml作为阳性参考值,对两组患者PCT浓度、C反应蛋白(CRP)指标进行横断面研究。结果感染组PCT阳性例数与对照组比较,差异无统计学意义(P>0.05),感染组平均PCT水平却明显高于对照组,差异有统计学意义(P<0.05)。PCT、CRP的受试者操作特征曲线(ROC)与曲线下面积(AUC)分别是0.822、0.643,CRP的最佳临界点为21.800 mg/l,PCT的最佳临界点为0.790 ng/ml,PCT的特异度与灵敏度均高于CRP。结论PCT可以作为肝癌合并细菌感染患者的辅助诊断指标,本研究初步得出感染临界点为0.790ng/ml,故不能简单以超过0.5 ng/ml来判断是否存在细菌感染。
Objective To explore the clinical value of serum procalcitonin(PCT)in antibacterial treatment of patients with liver cancer complicated with bacterial infection.Methods A total of 100 patients with liver cancer admitted to Shengzhou People’s Hospital from January 2019 to June 2020 were selected as the research objects.According to whether they were complicated with bacterial infection,the patients were divided into the infection group and control group,with 50 cases in each group.PCT concentration>0.5 ng/ml was taken as the positive reference value,and the PCT concentration and C-reactive protein(CRP)index of the two groups were compared in a crosssectional study.Results Compared with the control group,there was no significant difference in the number of PCT-positive cases in the infected group(P>0.05),but the average PCT level in the infection group was obviously higher than that in the control group,and the difference was statistically significant(P<0.05).The receiver operator characteristic curve(ROC)and area under the cure(AUC)of PCT and CRP were 0.822 and 0.643,respectively.The optimal critical point of CRP and PCT was 21.800 mg/L and 0.790 ng/ml,respectively.The specificity and sensitivity of PCT were higher than those of CRP.Conclusion PCT can be used as an auxiliary diagnostic index for patients with liver cancer complicated with bacterial infection.This study initially concluded that the cut-off point for infection was 0.790 ng/ml,so the presence of bacterial infection cannot be determined simply by exceeding 0.5 ng/ml.
作者
张东萍
肖招英
邵燕
赵庆锋
徐孟秋
ZHANG Dongping;XIAO Zhaoying;SHAO Yan;ZHAO Qingfeng;XU Mengqiu(Department of Clinical Pharmacy,Shengzhou People's Hospital of Zhejiang Province(Shengzhou Branch of the First Affiliated Hospital of Zhejiang University School of Medicine),Zhejiang,Shengzhou 312400,China;Department of Infectious Diseases,Shengzhou People's Hospital,Zhejiang Province(Shengzhou Branch of the First Affiliated Hospital of Zhejiang University School of Medicine),Zhejiang,Shengzhou 312400,China)
出处
《中国医药科学》
2021年第3期203-205,共3页
China Medicine And Pharmacy
基金
浙江省嵊州市级科技计划项目(2019-66)。
关键词
血清降钙素原
肝癌
感染
抗菌治疗
Serum procalcitonin
Liver cancer
Infection
Antibacterial treatment
